VolitionRx Limited Expected to Earn Q1 2024 Earnings of ($0.11) Per Share (NYSE:VNRX)

VolitionRx Limited (NYSE:VNRX - Free Report) - Research analysts at Zacks Small Cap issued their Q1 2024 earnings estimates for shares of VolitionRx in a note issued to investors on Monday, April 8th. Zacks Small Cap analyst S. Ralston anticipates that the company will earn ($0.11) per share for the quarter. The consensus estimate for VolitionRx's current full-year earnings is ($0.44) per share. Zacks Small Cap also issued estimates for VolitionRx's Q2 2024 earnings at ($0.10) EPS, Q3 2024 earnings at ($0.09) EPS and Q4 2024 earnings at ($0.08) EPS.

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $2.50 target price on shares of VolitionRx in a report on Wednesday, March 27th.

VolitionRx Trading Up 4.1 %

Shares of NYSE VNRX traded up $0.03 during midday trading on Tuesday, reaching $0.76. The company's stock had a trading volume of 55,648 shares, compared to its average volume of 180,418. The company has a 50 day moving average price of $0.94 and a 200 day moving average price of $0.84. VolitionRx has a one year low of $0.55 and a one year high of $2.10. The company has a market cap of $62.37 million, a price-to-earnings ratio of -1.49 and a beta of 1.35.

VolitionRx (NYSE:VNRX - Get Free Report) last released its earnings results on Monday, March 25th. The company reported ($0.11) EPS for the quarter. The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.50 million.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Vanguard Group Inc. boosted its stake in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 16.1% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 629,639 shares of the company's stock after purchasing an additional 87,195 shares during the period. Vanguard Group Inc. owned about 0.80% of VolitionRx worth $451,000 at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.